In particular, EGFR-mutant tumors harbor a low tumor mutational burden (TMB) and a “cold” tumor microenvironment, characterized by restricted T-cell clonality, and these features appear culpable to lack of benefit from PD-(L)1 inhibitors [58,59,60,61,62]. Here, EGFR is linked to neoplasm.